Published by Josh White on 21st October 2019
(Sharecast News) - Bioventix, which specialises in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, reported a 6% improvement in revenue for the year on Monday, to £9.3m.
URL: http://www.digitallook.com/dl/news/story/29734915/...